<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22730" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hemoglobin C Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Karna</surname>
            <given-names>Bibek</given-names>
          </name>
          <aff>B.P. Koirala Institute Of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jha</surname>
            <given-names>Suman K.</given-names>
          </name>
          <aff>B.P. Koirala Institute of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Zaabi</surname>
            <given-names>Eiman</given-names>
          </name>
          <aff>Emirates University in AL Ain</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bibek Karna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suman Jha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Eiman Al Zaabi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22730.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hemoglobin C is a common hemoglobin variant that has a single amino acid substitution (lysine substituted for the glutamate) in the sixth position of the beta-globin chain. The patients with hemoglobin C trait (HbAC) are phenotypically normal, while patients with hemoglobin C disease (HbCC) may have chronic hemolytic anemia. This activity reviews the evaluation and management of hemoglobin C disease and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of hemoglobin C disease.</p></list-item><list-item><p>Summarize the appropriate evaluation of hemoglobin C disease.</p></list-item><list-item><p>Outline the management options available for hemoglobin C disease.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to advance the delivery of care and improve outcomes for patients with hemoglobin C disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22730&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22730">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22730.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The normal adult hemoglobin is a hetero-tetramer consisting of two pairs of globin polypeptide chains: one pair of alpha chains and the next pair of non-alpha chains. These polypeptide chains are folded such that the four heme groups lie in the clefts on the surface of the molecule forming the structure of the hemoglobin.&#x000a0;</p>
        <p>Hemoglobin analysis reveals three different patterns of normal hemoglobin in an adult. These are Hb A (95 to 98%) containing two alpha and two beta chains,&#x000a0;Hb A2 (2% to 3%) containing two alpha and two delta chains, and&#x000a0;Hb F (less than 1%) containing two alpha and two gamma chains.&#x000a0;</p>
        <p>Hemoglobin C (Hb C), on the other hand,&#x000a0;is one of the common structural variants of normal hemoglobin in which lysine is substituted for the glutamate in the sixth position of the beta-globin chain making it less soluble than Hb A. Hemoglobin C can either be in the homozygous states (Hb CC) or in the heterozygous states (Hb SC, Hb AC). Persons with hemoglobin C trait (Hb AC) are phenotypically normal and generally do not show any symptoms while persons with hemoglobin C disease (Hb CC) may present with mild chronic hemolysis, splenomegaly, and jaundice.&#x000a0;Although hemoglobin C disease is a mild disease and does not develop into serious clinical complications, its inheritance with other hemoglobinopathies such as hemoglobin S (Hb SC) may have serious consequences. Thus, utmost care, treatment, and genetic counseling must be provided to these patients.</p>
      </sec>
      <sec id="article-22730.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hemoglobin C is caused due to mutation in the beta-globin chain in which glutamate (acidic) is replaced by lysine (basic) in the sixth position of the beta-globin chain. This mutation makes Hb C less soluble than Hb A, forming hexagonal crystals (HbC crystals as seen in the peripheral smear).</p>
        <p>Hemoglobin C is a hemoglobinopathy that is hereditary. It is an autosomal recessive disorder that results from the biparental inheritance of the allele that codes for Hemoglobin C. If both the parents are carriers of hemoglobin C, there is a 25% chance of having hemoglobin C disease in a child, 50% chance of having a child who is a carrier, and 25% chance of having a child who is neither a carrier nor have hemoglobin C disease.</p>
        <p>The mutation present in some of the hemoglobinopathies (Hb S, Hb C, Hb E) may be an evolutionary modification due to the effect of some selective external forces like malaria as in the heterozygous form, these mutations protect carriers from&#x000a0;dying of malarial infection. The cohort study was done on three hundred children in Bandiagara, Mali, found out that both HbC and HbS traits provide protection from clinical falciparum malaria.<xref ref-type="bibr" rid="article-22730.r1">[1]</xref>&#x000a0;One in-vitro study has proposed the mechanism that the hemoglobinopathies (HbS, HbC) impair protein export in <italic toggle="yes">Plasmodium falciparum</italic> infected erythrocytes. This provides a mechanistic explanation for reduced disease mediating cytoadherence of parasitized hemoglobinopathic erythrocytes.<xref ref-type="bibr" rid="article-22730.r2">[2]</xref></p>
        <p>A retrospective study performed on all sickle cell disease patients who underwent red cell exchange transfusions (RBCEx) at the University of Arkansas found out the presence of other Hemoglobin variants too in the recipients. This new hemoglobin variant present in the patients was acquired as a result of RBCEx. The most commonly acquired hemoglobin variant was hemoglobin C (64/66 occurrences).<xref ref-type="bibr" rid="article-22730.r3">[3]</xref></p>
      </sec>
      <sec id="article-22730.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Given the protective effect of hemoglobin C in malaria infection, it is almost understandable that this mutation has a high prevalence in Atlantic West Africa and South East Asia. Hemoglobin C is also found in a diverse population in Africa, South and Central America, and Southern Europe.</p>
        <p>A retrospective study performed in 111 cases of hemoglobin C disease over 12 years in Morocco showed the mean age at the time of diagnosis as 38 years (ranging between 4 and 80 years). Also, the biochemical tests contributed to the diagnosis and revealed varied etiological groups in the study population: heterozygous A/C (75%), homozygous C/C (8%), double heterozygous S/C (9%), C/beta +/- Thal (6%), C/ O - Arab (2%).<xref ref-type="bibr" rid="article-22730.r4">[4]</xref></p>
      </sec>
      <sec id="article-22730.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The substitution of lysine for glutamic acid in the sixth position of the beta-globin chain induces an electrostatic interaction between positively charged&#x000a0;beta-6-lysyl groups and negatively charged adjacent molecules, leading to the decreased solubility of HbC in red cells. Due to this, crystal formation occurs, leading to increased blood viscosity and decreased red blood cell life span. But, unlike sickle cell disease, which is caused due to the substitution of valine for glutamic acid, Hb C does not cause intracellular polymerization during low oxygen tension. Thus, in general, the vaso-occlusive crisis is not seen with hemoglobin C disease unless it is combined with sickle cell (Hb SC).</p>
        <p>Several heterozygous combinations of hemoglobin C with other hemoglobin variants are seen. One case study reported a young woman with compound heterozygosity for Hb-D-Ibadan and HbC, a rare Hb combination that was previously not identified. This combination was detected during prenatal screening, and HbD-Ibadan was present in excess amount than HbC in the combination (70.3% to 24.4%). The combination is clinically silent and demonstrates thalassemia-minor-like red cell indices.<xref ref-type="bibr" rid="article-22730.r5">[5]</xref>&#x000a0;</p>
        <p>Hemoglobin C-Harlem is another rare condition that has the same electrophoretic mobility as that of HbC on alkaline electrophoresis. But this molecule, similar to HbSS, can polymerize when deoxygenated and hence has a clinical course similar to sickle cell disease.<xref ref-type="bibr" rid="article-22730.r6">[6]</xref></p>
      </sec>
      <sec id="article-22730.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Hemoglobin C trait (HbAC) is clinically silent. Hemoglobin C disease (HbCC) is also a mild disorder, and most people do not have any symptoms. But some patients may experience mild hemolytic anemia and hence may complain of symptoms like fatigue, lightheadedness, weakness, and paleness of the skin. On physical examination, there can be mild to moderate splenomegaly, and occasionally jaundice may occur. A retrospective study which was done in 111 cases of hemoglobin C disease also found out that the most important reason for prescription of hemoglobin analysis in these patients was splenomegaly and anemic syndrome.<xref ref-type="bibr" rid="article-22730.r4">[4]</xref> Some patients, due to continued chronic hemolysis, may develop cholelithiasis from pigmented gall stones composed of dark-colored contents of red blood cells.</p>
        <p>Individuals with combined sickle cell hemoglobin C disease (HbSC) present with symptoms that are generally similar to but less severe than hemoglobin SS disease. Since hemoglobin C does not polymerize like hemoglobin S, there is very little sickling in this combination. Thus, an acute vaso-occlusive crisis does occur but less frequently. A cross-sectional study that was done to compare the sickle cell anemia and hemoglobin SC disease from 2013 to 2014 in 200 patients with sickle cell disease patients (141 with SCA and 59 with HbSC) showed HbSC genotype was associated more with blood viscosity while HbSS was associated more with sickling and endothelial dysfunction. Also, the clinical events were more frequent in HbSS patients.<xref ref-type="bibr" rid="article-22730.r7">[7]</xref>&#x000a0;The two most important complications that may occur more frequently in HbSC are vascular retinopathy and avascular necrosis of the femoral head. A cohort study done in 461 infants with Hemoglobin SC disease showed acute splenic sequestration in 14.8%, overt stroke in 0.2%, incidence of painful vaso-occlusive episodes was 51 per 100 patient-years while that of infections was 62.2 episodes per 100 patient-years. Similarly, retinopathy was observed in 20.3% of 59 children who underwent ophthalmoscopy, and avascular necrosis was detected in seven out of twelve patients evaluated, predominantly in the left femur.<xref ref-type="bibr" rid="article-22730.r8">[8]</xref></p>
      </sec>
      <sec id="article-22730.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For asymptomatic patients, routine screening laboratory studies are not necessary. Evaluation should be done for patients with a moderate to severe clinical course. The lab results depend on whether the patient is a carrier (HbAC) or has a disease (HbCC). But most importantly, hemoglobin C in both of the states, the homozygous (HbCC), and in the heterozygous (HbAC, HbSC) induces red cell dehydration resulting in red cells with increased mean corpuscular hemoglobin concentration (MCHC). A study performed on a 17-year-old male with hereditary xerocytosis-hemoglobin C trait showed that the hemoglobin C accentuates the erythrocyte dehydration of hereditary xerocytosis.<xref ref-type="bibr" rid="article-22730.r9">[9]</xref></p>
        <p>The most common method used to detect hemoglobinopathies is hemoglobin electrophoresis or high-performance liquid chromatography (HPLC). Patients who are homozygous for hemoglobin C disease mostly show HbC; HbA is absent, and HbF is slightly increased while patients who are heterozygous for hemoglobin C disease may show 30% to 40% HbC, 50% to 60% HbA, and HbA2 is slightly increased.</p>
        <p>Peripheral smear or blood film findings: P.S. reveals the presence of hexagonal or tetragonal crystals due to decreased solubility of HbC. In addition to the presence of crystals, there are red blood cells microcytosis, irregularly contracted cells, and numerous target cells, as shown in the picture.</p>
        <p>In the patients with the hemoglobin C trait, hemoglobin concentrations are usually within the low normal to the normal range. The life span of red cells gets decreased but despite this, the reticulocyte counts are not increased. The peripheral smear may show target cells and intracellular crystals. Likewise, the patients with Hemoglobin C disease, as mentioned earlier, show the lab findings suggestive of hemolysis: increased LDH, reticulocyte count, and direct bilirubin. The peripheral smear shows microcytosis, a large number of target cells, spherocytes, and crystallized hemoglobin.</p>
        <p>A study showed that in a diabetic patient presenting with "HbS" or "HbC," there is a considerable false decrease in the values for glycosylated hemoglobin (HbA1c) despite persistent hyperglycemia and this decrease is proportional to the percentage of abnormal hemoglobin.<xref ref-type="bibr" rid="article-22730.r10">[10]</xref>&#x000a0;</p>
        <p>There is a study describing the use of miniaturized paper-based microchip electrophoresis for point of care hemoglobin testing in low resource settings, which identifies hemoglobin variants easily and affordably with the sensitivity of 100% and an accuracy of 98.4%.<xref ref-type="bibr" rid="article-22730.r11">[11]</xref>&#x000a0;</p>
        <p>A large cohort study done in Brazil described the use of an automated pyrosequencing technique for large-scale confirmatory testing of hemoglobin mutation, which could also describe&#x000a0;beta+ and&#x000a0;beta- mutation present in sickle cell disease.<xref ref-type="bibr" rid="article-22730.r12">[12]</xref></p>
        <p>Likewise, there is a study describing the use of a new polymerase chain reaction test (LAMP assay) that can be performed directly on dried blood cards without DNA extraction and has an accuracy of 100% for detecting HbS and HbC.<xref ref-type="bibr" rid="article-22730.r13">[13]</xref></p>
      </sec>
      <sec id="article-22730.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>In most patients,&#x000a0;no treatment is required. As with chronic hemolysis, body stores of folic acid can get depleted; thus, folic acid is indicated, which helps produce new red cells and improve the symptoms of anemia. Despite splenomegaly, the splenic function remains normal, and hence long-term antibiotic prophylaxis is not indicated.</p>
        <p>A study showed that in patients with sickle cell hemoglobin C disease undergoing cardiopulmonary bypass, the use of complete exchange blood transfusion makes bypass surgery relatively safe with enhanced outcomes.<xref ref-type="bibr" rid="article-22730.r14">[14]</xref>&#x000a0;Likewise, there is also a study demonstrating better maternal and fetal outcomes in sickle cell hemoglobin C disease patients receiving prophylactic transfusions during pregnancy.<xref ref-type="bibr" rid="article-22730.r15">[15]</xref></p>
      </sec>
      <sec id="article-22730.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Following important differential diagnoses should be considered when hemoglobin C disease is suspected:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sickle cell anemia</p>
          </list-item>
          <list-item>
            <p>Beta thalassemia</p>
          </list-item>
          <list-item>
            <p>Other hemolytic anemias</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22730.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Hemoglobin C is a benign hemoglobinopathy that can cause mild hemolytic anemia. Overall people with hemoglobin C have normal growth and development and a normal life expectancy.</p>
      </sec>
      <sec id="article-22730.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Hemoglobin C disease, due to continued hemolysis may produce cholelithiasis due to pigmented gallstones.</p>
        <p>A patient with combined sickle cell hemoglobin C disease (HbSC) can develop vascular retinopathy, avascular necrosis, and renal medullary microvascular thrombosis. A study performed in a patient with hemoglobin SC disease showed peritubular capillary and vasa recta thrombi and capillary basement membrane alterations mostly involving the renal medulla.<xref ref-type="bibr" rid="article-22730.r16">[16]</xref></p>
      </sec>
      <sec id="article-22730.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Hemoglobin C disease is a mild disorder and usually, no treatment is needed. There are no restrictions on any physical activities. Similarly, there is no requirement for any special diet. For couples who are at high risk for hemoglobin C disease and who wish to have a baby, genetic counselors should be consulted.</p>
      </sec>
      <sec id="article-22730.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hemoglobin C is a benign hemoglobinopathy. It is caused due to mutation in the beta-globin chain of hemoglobin. The patient may be asymptomatic or may show signs and symptoms of anemia due to chronic hemolysis and hence requires the efforts of an interprofessional health care team. Interprofessional care may be useful and includes a geneticist, hematologist, and ophthalmologist.</p>
        <p>Once the diagnosis is made, the hematologist has an important role as a primary caretaker in the management of the patients. As there is a high possibility of&#x000a0;co-inheritance of this disease with other hemoglobinopathies, thus geneticists should be involved. Genetic counseling also plays a vital role if the high-risk couples for this disease wish to have a baby. In patients with HbSC disease, vascular retinopathy might occur. Thus, ophthalmologists should take care of these patients on a regular follow-up basis and help prevent and manage retinopathy.[Level 5]</p>
      </sec>
      <sec id="article-22730.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22730&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22730">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/hemoglobin-c-disease/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22730">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22730/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22730">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22730.s15">
        <title>References</title>
        <ref id="article-22730.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Travassos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Coulibaly</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Laurens</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Demb&#x000e9;l&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tolo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kon&#x000e9;</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Traor&#x000e9;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Niangaly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guindo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Takala-Harrison</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Kouriba</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lyke</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Diallo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Doumbo</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Plowe</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Thera</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children.</article-title>
            <source>J Infect Dis</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>212</volume>
            <issue>11</issue>
            <fpage>1778</fpage>
            <page-range>1778-86</page-range>
            <pub-id pub-id-type="pmid">26019283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Srismith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dittmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouermi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bisseye</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Simpore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cyrklaff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lanzer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin S and C affect protein export in Plasmodium falciparum-infected erythrocytes.</article-title>
            <source>Biol Open</source>
            <year>2015</year>
            <month>Feb</month>
            <day>20</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>400</fpage>
            <page-range>400-10</page-range>
            <pub-id pub-id-type="pmid">25701664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cottler-Fox</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drobena</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin Variants Acquired Post-Exchange Transfusion in Pediatric Sickle Cell Disease (SCD) Patients.</article-title>
            <source>Ann Clin Lab Sci</source>
            <year>2015</year>
            <season>Fall</season>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>627</fpage>
            <page-range>627-30</page-range>
            <pub-id pub-id-type="pmid">26663791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ouzzif</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>El Maataoui</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oukhedda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Messaoudi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mikdam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdellatifi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Doghmi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobinosis C in Morocco : A report of 111 cas.</article-title>
            <source>Tunis Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>95</volume>
            <issue>12</issue>
            <fpage>229</fpage>
            <page-range>229-233</page-range>
            <pub-id pub-id-type="pmid">29878289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kundrapu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Janaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meyerson</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Compound Heterozygosity for Hb D-Ibadan (HBB: c.263C&#x0003e;A) and Hb C (HBB: c.19G&#x0003e;A).</article-title>
            <source>Hemoglobin</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>269</fpage>
            <page-range>269-271</page-range>
            <pub-id pub-id-type="pmid">30604644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zacharia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maronge</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Brazda</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Boulmay</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin SO-Arab and &#x003b1;-thalassemia diagnosed in an adult: A case-based review of the hemoglobinopathies.</article-title>
            <source>Am J Med Sci</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>346</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-7</page-range>
            <pub-id pub-id-type="pmid">23221516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aleluia</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>TCC</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>RQ</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>da Guarda</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>BLA</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>CVB</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>da Paz</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JRD</given-names>
              </name>
              <name>
                <surname>Cerqueira</surname>
                <given-names>BAV</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Comparative study of sickle cell anemia and hemoglobin SC disease: clinical characterization, laboratory biomarkers and genetic profiles.</article-title>
            <source>BMC Hematol</source>
            <year>2017</year>
            <volume>17</volume>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">28932402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezende</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Vieira</surname>
                <given-names>LLM</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Belis&#x000e1;rio</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Viana</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Clinical and hematological profile in a newborn cohort with hemoglobin SC.</article-title>
            <source>J Pediatr (Rio J)</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>94</volume>
            <issue>6</issue>
            <fpage>666</fpage>
            <page-range>666-672</page-range>
            <pub-id pub-id-type="pmid">29195085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Voelkel</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Lezon-Geyda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schulz</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Hemoglobin C trait accentuates erythrocyte dehydration in hereditary xerocytosis.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>64</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">28121068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aleyassine</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Low proportions of glycosylated hemoglobin associated with hemoglobin S and hemoglobin C.</article-title>
            <source>Clin Chem</source>
            <year>1979</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1484</fpage>
            <page-range>1484-6</page-range>
            <pub-id pub-id-type="pmid">455690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasan</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Fraiwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alapan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Akkus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Rezac</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Kocmich</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Creary</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Oginni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Olanipekun</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Hassan-Hanga</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jibir</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Gambo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bharti</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Riolueang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ngimhung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suksangpleng</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thota</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shanmugam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viprakasit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Piccone</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Obaro</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gurkan</surname>
                <given-names>UA</given-names>
              </name>
            </person-group>
            <article-title>Paper-based microchip electrophoresis for point-of-care hemoglobin testing.</article-title>
            <source>Analyst</source>
            <year>2020</year>
            <month>Apr</month>
            <day>07</day>
            <volume>145</volume>
            <issue>7</issue>
            <fpage>2525</fpage>
            <page-range>2525-2542</page-range>
            <pub-id pub-id-type="pmid">32123889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Martino</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Alencar</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Loureiro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carneiro-Proietti</surname>
                <given-names>ABF</given-names>
              </name>
              <name>
                <surname>M&#x000e1;ximo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Mota</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>DOW</given-names>
              </name>
              <name>
                <surname>Gaburo Junior</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sabino</surname>
                <given-names>EC</given-names>
              </name>
              <collab>International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III)</collab>
            </person-group>
            <article-title>Use of an automated pyrosequencing technique for confirmation of sickle cell disease.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>e0216020</fpage>
            <pub-id pub-id-type="pmid">31830127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Detemmerman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bours</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boemer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Innovative PCR without DNA extraction for African sickle cell disease diagnosis.</article-title>
            <source>Hematology</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>181</fpage>
            <page-range>181-186</page-range>
            <pub-id pub-id-type="pmid">28929945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullins</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mister</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Sickle Cell Hemoglobin C Disease Patient Undergoing Coronary Artery Bypass Grafting with Complete Exchange Blood Transfusion during Cardiopulmonary Bypass.</article-title>
            <source>J Extra Corpor Technol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-119</page-range>
            <pub-id pub-id-type="pmid">29921991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benites</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Benevides</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Gilli</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patients.</article-title>
            <source>Transfusion</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-24</page-range>
            <pub-id pub-id-type="pmid">26337929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22730.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissonnette</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Henriksen</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stankus</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Medullary Microvascular Thrombosis and Injury in Sickle Hemoglobin C Disease.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2016</year>
            <month>May</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1300</fpage>
            <page-range>1300-4</page-range>
            <pub-id pub-id-type="pmid">26546258</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
